Xcout Intel
Embold Therapeutics, Inc.
Embold Therapeutics, Inc. is a life-sciences company located in Redwood City, California.
Subscribe to see Embold Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Embold Therapeutics, Inc. at a glance
Embold Therapeutics, Inc. is a biotechnology company headquartered in United States. It has raised at least $4.8M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $2.3M in July 2026. Xcout tracks 6 named people at Embold Therapeutics, Inc., including Gjalt Huisman (CEO).
Embold Therapeutics, Inc. leadership
- Gjalt HuismanCEO
- Gjalt W. HuismanChief Executive Officer
- Daniel SteinFounder and CEO
- Vesna MitchellHead of Molecular Biology Research Operations
- Victoria WongHead of Translational Sciences
- Gjalt W. HuismanExecutive Officer
Embold Therapeutics, Inc. funding rounds
At least $4.8M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $2.3M | 4 named | |
| SEC Form D filing | $2.5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Embold Therapeutics, Inc. news
- FundingPrivate placement (Form D)
Investors
Embold Therapeutics, Inc. competitors
A few of Embold Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Rubedo Life Sciences is a clinical-stage biopharmaceutical company headquartered in Sunnyvale and Mountain View, California, developing a broad portfolio of innovative therapies.
Trellis Bioscience, Inc. is a clinical-stage biotechnology company located in Redwood City, California, focused on developing antibody-based therapeutics.
Encoded Therapeutics is a biotechnology company headquartered in South San Francisco, California, dedicated to developing next-generation genetic medicines designed to address the root causes of genetic diseases.
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
Bolden Therapeutics, Inc. is a privately held biotechnology company founded in 2019 and headquartered in Providence, Rhode Island, with corporate office space in Boston, Massachusetts. The company is dedicated to developing first-in-class therapeutics.
Get Embold Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Embold Therapeutics, Inc. in Xcout Intel
- 6 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access